Protein kinase CK2 content in GL261 mouse glioblastoma
Ferrer-Font, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Alcaraz Muñoz, Estefania (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Plana i Coll, Maria (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Itarte, Emilio (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Arús i Caraltó, Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)

Date:	2016
Abstract:	Glioblastoma (GBM) is the most prevalent and aggressive human glial tumour with a median survival of 14-15 months. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment. Unfortunately, chemoresistence always ensues with concomitant tumour regrowth. Protein kinase CK2 (CK2) contributes to tumour development, proliferation, and suppression of apoptosis in cancer and it is overexpressed in human GBM. Targeting CK2 in GBM treatment may benefit patients. With this translational perspective in mind, we have studied the CK2 expression level by Western blot analysis in a preclinical model of GBM: GL261 cells growing orthotopically in C57BL/6 mice. The expression level of the CK2 catalytic subunit (CK2α) was higher in tumour (about 4-fold) and in contralateral brain parenchyma (more than 2-fold) than in normal brain parenchyma (p < 0. 05). In contrast, no significant changes were found in CK2 regulatory subunit (CK2β) expression, suggesting an increased unbalance of CK2α/CK2β in GL261 tumours with respect to normal brain parenchyma, in agreement with a differential role of these two subunits in tumours.
Grants:	Ministerio de Ciencia e Innovación SAF 2011-23870 Ministerio de Economía y Competitividad SAF2014-52332-R Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-191
Rights:	Tots els drets reservats.
Language:	Anglès
Document:	Article ; recerca ; Versió sotmesa a revisió
Subject:	Glioma ; CK2 content ; Preclinical brain tumor ; GBM therapeutic targets
Published in:	Pathology & oncology research, Vol. 22, Issue 3 (July 2016) , p. 633-637, ISSN 1219-4956

DOI: 10.1007/s12253-015-9987-7

Pre-print 17 p, 1.8 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles